Bill B, The only viable option to optimize shareholder value
would be a BO. Any deal that JT makes which makes a BO less
likely would have a negative impact on the share price. So
long as JT does not announce any JV or partnership deal he
helps to keep the BO option alive. One way to look the
situation:
If you are a BP, let's say you're a Roche or a Novartis. Would you
want to do a JV or partnership deal with AMRN knowing that they
have a side deal with another BP, let's say AZN for the UK? That
would place both BP at the whim and mercy of AMRN. Would not one
BP prefer to plan the entire campaign without the other BPs
involvement? Of course. If BP cannot be in total control;
of product sourcing, pricing, distribution, long term planning & strategy;
then they are at a disadvantage. This is why BP would not want to
consider such an arrangement. Either JT executes a BP takeout of AMRN
or the shareholders will face an excruciating torturous journey, that
none of us want or deserve.
News 
Market Data 
Discover 
